[ CAS No. 13139-12-3 ] {[proInfo.proName]}

Name: 13139-12-3|tert-Butyl (2,5-dioxopyrrolidin-1-yl) carbonate|98%
Brand: Ambeed
SKU: A145479
Price: 5.0 USD
Availability: InStock
Rating: 92 (32 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 13139-12-3

Structure of 13139-12-3 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 13139-12-3 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 13139-12-3 ]

SDS Specification

Alternatived Products of [ 13139-12-3 ]

Product Details of [ 13139-12-3 ]

CAS No. :	13139-12-3	MDL No. :	MFCD00037903
Formula :	C₉H₁₃NO₅	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	VTGFSVGZCYYHLO-UHFFFAOYSA-N
M.W :	215.20	Pubchem ID :	83168
Synonyms :

Calculated chemistry of [ 13139-12-3 ]

Physicochemical Properties

Num. heavy atoms :	15
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.67
Num. rotatable bonds :	4
Num. H-bond acceptors :	5.0
Num. H-bond donors :	0.0
Molar Refractivity :	53.27
TPSA :	72.91 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.17 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.07
Log Po/w (XLOGP3) :	0.62
Log Po/w (WLOGP) :	0.62
Log Po/w (MLOGP) :	0.34
Log Po/w (SILICOS-IT) :	0.16
Consensus Log Po/w :	0.76

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.3
Solubility :	10.8 mg/ml ; 0.05 mol/l
Class :	Very soluble
Log S (Ali) :	-1.73
Solubility :	4.05 mg/ml ; 0.0188 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.75
Solubility :	38.2 mg/ml ; 0.177 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.42

Safety of [ 13139-12-3 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P264-P270-P272-P280-P301+P312-P302+P352-P330-P333+P313-P363-P403-P501	UN#:	N/A
Hazard Statements:	H302-H317	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 13139-12-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 13139-12-3 ]
Downstream synthetic route of [ 13139-12-3 ]

[ 13139-12-3 ] Synthesis Path-Upstream 1~3

1
[ 110-72-5 ]
[ 13139-12-3 ]
[ 113283-93-5 ]

Reference： [1] Organic Preparations and Procedures International, 1998, vol. 30, # 3, p. 339 - 348

2
[ 13139-12-3 ]
[ 111-40-0 ]
[ 117499-16-8 ]

Reference： [1] Organic Preparations and Procedures International, 1998, vol. 30, # 3, p. 339 - 348

3
[ 13139-12-3 ]
[ 107885-67-6 ]
[ 625471-04-7 ]

Yield	Reaction Conditions	Operation in experiment
54%	at -78 - 20℃; for 4.16667 - 4.25 h;	Example 26 2-R (AMINOCARBONYL) AMINOL-N-R (3S)-AZEPAN-3-VLL-5-(4-METHOXD7PHENVL) THIOPHENE-3 carboxamide hydrochloride (S)-3-AMINO-AZEPANE-1-CARBOXYLIC acid tert-butyl ester. (S)-Azepan-3-ylamine (5g ; 43.8 mmol) was dissolved in 100 mL of anhydrous CH2C12 and cooled to-78 °C while stirring with a magnetic stirring bar. In another flask N-(TERT-BUTOXYCARBONYLOXY) SUCCINIMIDE [BOC-OSU] (9.7 g; 45 mmol) was dissolved in 50 ML of anhydrous CH2C12. To the stirred solution of the amine was added the solution of the SUCCINIMIDE over a period of 10-15 minutes so as to keep the reaction mixture at-78 °C while stirring. After the addition was complete, the reaction was allowed to warm to room temperature and then stirred for an additional 4h or until the reaction was complete by TLC (Ninhydrin; Rf 0.3 ; 0.1 : 1: 10 NH4OH, MeOH ; CH2C12). The reaction mixture was washed with 50 mL of H20. The aqueous layer was brought to a pH >13 by the addition of 6N NAOH and extracted with CH2C12 (3 x 100 mL). The organic layer was dried over Na2C03, filtered, and concentracted in a vacuum to yield pure (S)-3-AMINO-AZEPANE-L-CARBOXYLIC acid tert- butyl ester as a viscous oil (5.1 g, 54percent).
54%	at -78℃; for 4.16667 - 4.25 h;	tert-butyl (3S)-3-aminoazepane-1-carboxylate.; (3S)-azepan-3-amine (5g ; 43.8 mmol) was dissolved in 100 mL of anhydrous CH2Cl2 and cooled to-78 °C while stirring with a magnetic stirring bar. In another flask N- (tert-Butoxycarbonyloxy) succinimide [Boc-OSu] (9.7g ; 45 mmol) was dissolved in 50 mL of anhydrous CH2Cl2. To the stirred solution of the amine was added the solution of the succinimide over a period of 10-15 minutes so as to keep the reaction mixture at-78 °C while stirring. After the addition was complete, the reaction was allowed to warm to room temperature and then stirred for an additional 4h or until the reaction was complete by TLC (Ninhydrin; Rf 0. 3; 0.1 : 1 : 10 NH40H, MeOH ; CH2C12). The reaction mixture was washed with 50 mL of H20. The aqueous layer was brought to a pH >13 by the addition of 6N NaOH and extracted with CH2Cl2 (3 x 100mL). The organic layer was dried over Na2C03, filtered, and concentrated in vacuo to yield pure title compound as a viscous oil (5. 1g, 54percent). 1H NMR (d6-DMSO, d 3.4, m, 2H; d 2.89, m, 1H; d 2.71, m, 1H ; d 2.54, m, 1H; d 1.54, m, 3H; d 1.34, m, 3H ; d 1.27, s, 9H; d 1.12, m, 2H), LC/MS (APCI, ES, M+H=215).

Reference： [1] Patent: WO2005/16909, 2005, A1, . Location in patent: Page/Page column 68
[2] Patent: WO2005/66163, 2005, A2, . Location in patent: Page/Page column 55-26

[ 13139-12-3 ] Synthesis Path-Downstream 1~88

1
[ 13139-12-3 ]
[ 6945-92-2 ]
[ 3842-39-5 ]
[ 3842-40-8 ]

Reference： [1]Tetrahedron Letters,1991,vol. 32,p. 2765 - 2768

2
[ 13139-12-3 ]
[ 96745-80-1 ]
[ 96758-74-6 ]

Reference： [1]Journal of Organic Chemistry,1985,vol. 50,p. 2660 - 2664

3
[ 13139-12-3 ]
[1,4,7]Triazonane-1,4-dicarboxylic acid dibenzyl ester [ No CAS ]
[1,4,7]Triazonane-1,4,7-tricarboxylic acid dibenzyl ester tert-butyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

4
[ 13139-12-3 ]
[ 124-20-9 ]
[ 83392-10-3 ]

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348

5
[ 13139-12-3 ]
[ 71-44-3 ]
[ 140652-55-7 ]

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348

6
[ 13139-12-3 ]
[ 589-37-7 ]
[ 210240-75-8 ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; at -40 - 20℃;	To a pre-cooled solution of (3-amino-1 -ethylpropyl)amine (1.27 mL, 10.6 mmol) in CH2CI2 (50 mL) at -40 0C was dropwisely added a pre-cooled solution of 1-([(1 ,1- dimethylethyl)oxy]carbonyl}oxy)-2,5-pyrrolidinedione (2.22 g, 10.3 mmol) in CH2CI2 (50 mL) via a cannula ) at -40 0C. After stirring for 3.5 hr at -40 0C, the reaction mixture was warmed up to rt and stirred overnight. The reaction was quenched with 1 N aqueous HCI (30 mL) and extracted with CH2CI2 (30 ml_ x 2). The aqueous solution was basified to pH 1 1-12 with cold 1 N aqueous NaOH followed by extraction with EtOAc (50 mL x 2). The combined organic solution was dried over K2CO3, filtered, and concentrated to provide the title compound which was used for the next reaction without further purification

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348
[2]Patent: WO2006/29210,2006,A2 .Location in patent: Page/Page column 116-117

7
[ 13139-12-3 ]
[ 111-41-1 ]
[ 208577-84-8 ]

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348

8
[ 13139-12-3 ]
[ 111-40-0 ]
[ 117499-16-8 ]

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348

9
[ 13139-12-3 ]
[ 811-93-8 ]
[ 95034-05-2 ]

Reference： [1]Organic Preparations and Procedures International,1998,vol. 30,p. 339 - 348

11
[ 13139-12-3 ]
[ 294-90-6 ]
[ 913542-69-5 ]

Yield	Reaction Conditions	Operation in experiment
100%	In chloroform; at 20℃; for 31h;	N-(tert-Butoxycarbonyloxy)succinimide (2.50 g, 11.62 mmol) inchloroform (30 mL) was added dropwise into the solution of1,4,7,10-tetraazacyclododecane (1.00 g, 5.80 mmol) in CHCl3(50 mL) during 7 h. The reaction mixture was stirred 24 h at roomtemperature and the solvent was removed under reduced pressure. The residue was suspended in aqueous NaOH (3 M, 50 mL) and theaqueous phase was extracted with CHCl3 (3 50 mL). The combinedextracts were dried with K2CO3 and evaporated to drynessto give 1,7-bis(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane(10) in quantitative yield.1,3,5-Tris(bromomethyl)benzene (7.65 g, 21.62 mmol) was dissolvedin CHCl3 (150 mL) and Na2CO3 (1.71 g, 16.15 mmol) wasadded. Compound 10 (1.08 g, 2.90 mmol) in CHCl3 (50 mL) wasadded dropwise into the reaction mixture during 11 hours at52 C. The reaction mixture was refluxed for 3 days at 62 C,filtrated, and evaporated to dryness. The residue was purified bysilica gel chromatography (40-70% EtOAc in hexane), giving 11 in27% yield (0.722 g). 1H NMR (500 MHz, CDCl3) d 7.33 (s, 6H), 4.45(s, 8H), 3.71 (s, 4H), 3.21-3.57 (m, 8H), 2.55-2.68 (m, 8H), 1.27(s, 18H). 13C NMR (100 MHz, CDCl3) dppm 155.8, 140.8, 138.5,129.9, 128.3, 79.3, 59.5, 55.2, 46.1, 32.9, 28.4. HRMS(ESI): obsd.921.0840 [M+H]+, Calcd. 921.0795 [M+H]+.
	With sodium hydroxide; In chloroform;	Synthesis of 1,7-bis(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane Cyclen (1.05 g) was dissolved in chloroform (50 mL), to which <strong>[13139-12-3]N-(tert-butoxycarbonyloxy)succinimide</strong> (2.62 g) was added, followed by stirring at room temperature. After 48 hours of stirring, the solvent was distilled off under reduced pressure. The resulting residue was dissolved in chloroform (50 mL), washed with an aqueous solution of sodium hydroxide, and dried over sodium sulfate. The solvent was distilled off under reduced pressure and the resulting product was dried in a vacuum to give the title compound (2.27 g).

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 6937 - 6940
[2]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 4285 - 4289
[3]Inorganica Chimica Acta,2016,vol. 452,p. 111 - 117
[4]Dalton Transactions,2017,vol. 46,p. 3192 - 3206
[5]Tetrahedron Letters,2010,vol. 51,p. 3436 - 3438
[6]Patent: US2012/219500,2012,A1
[7]Patent: JP2019/43902,2019,A .Location in patent: Paragraph 0034; 0035; 0036

12
[ 13139-12-3 ]
[ 1007596-94-2 ]
[ 1007596-95-3 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In methanol; at 20℃; for 2h;	Crude (3i?,4i?)-4-aminopiperidin-3-ol (12 mmol) was dissolved in DCM (50 ml), methanol (10 ml) and DIEA (2.3 grams; 3 ml; 18 mmol; 3 equiv.). Boc-OSu (-[(tert- butoxycarbonyl)oxy]pyrrolidine-2,5-dione) (2.7 grams; 12.6 mmol; 1.05 equiv.) was added in a single portion. The reaction mixture was stirred at room temperature for 2 hours and monitored by TLC (90: 10: 1 CHCl3 / methanol / NH4OH). The reaction mixture was concentrated to an oil.

Reference： [1]Patent: WO2008/20222,2008,A1 .Location in patent: Page/Page column 126

13
Gly-Ser-Lys-Ile-Leu-Leu-Thr-Cys(acetamidomethyl)-Ser-Leu-Asn(GlcNHAc)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys-Gly-SCH₂CH₂CO-Leu [ No CAS ]
[ 13139-12-3 ]
Boc-Gly-Ser-Lys(Boc)-Ile-Leu-Leu-Thr-Cys(acetamidomethyl)-Ser-Leu-Asn(GlcNHAc)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys(Boc)-Gly-SCH₂CH₂CO-Leu [ No CAS ]

Reference： [1]Bioscience, Biotechnology and Biochemistry,2006,vol. 70,p. 1338 - 1349

14
Gly-Ser-Lys-Ile-Leu-Leu-Thr-Cys(acetamidomethyl)-Ser-Leu-Asn(GlcNAc₂)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys-Gly-SCH₂CH₂CO-Leu [ No CAS ]
[ 13139-12-3 ]
Boc-Gly-Ser-Lys(Boc)-Ile-Leu-Leu-Thr-Cys(acetamidomethyl)-Ser-Leu-Asn(GlcNAc₂)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys(Boc)-Gly-SCH₂CH₂CO-Leu [ No CAS ]

Reference： [1]Bioscience, Biotechnology and Biochemistry,2006,vol. 70,p. 1338 - 1349

15
Gly-Ser-Lys-Ile-Leu-Leu-Thr-Ala-Ser-Leu-Asn(Man₃GlcNAc₂)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys-Gly-SCH₂CH₂CONH₂ [ No CAS ]
[ 13139-12-3 ]
Boc-Gly-Ser-Lys(Boc)-Ile-Leu-Leu-Thr-Ala-Ser-Leu-Asn(Man₃GlcNAc₂)-Asp-Ser-Ala-Thr-Glu-Val-Thr-Gly-His-Arg-Trp-Leu-Lys(Boc)-Gly-SCH₂CH₂CONH₂ [ No CAS ]

Reference： [1]Tetrahedron,2007,vol. 63,p. 9685 - 9690

16
[ 13139-12-3 ]
[ 913542-70-8 ]

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 6937 - 6940

17
[ 13139-12-3 ]
[ 174310-75-9 ]

Reference： [1]Tetrahedron Letters,2000,vol. 41,p. 8157 - 8162

18
[ 13139-12-3 ]
[ 316813-68-0 ]

Reference： [1]Tetrahedron Letters,2000,vol. 41,p. 8157 - 8162

19
[ 13139-12-3 ]
[ 174138-04-6 ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

20
[ 13139-12-3 ]
[ 174138-05-7 ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

21
[ 13139-12-3 ]
4,7-Bis-tert-butoxycarbonylmethyl-[1,4,7]triazonane-1-carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

22
[ 13139-12-3 ]
7-tert-Butoxycarbonylmethyl-[1,4,7]triazonane-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

23
[ 13139-12-3 ]
tert-butyl 4,7-bis((diethoxyphosphoryl)methyl)-1,4,7-triazacyclononane-1-carboxylate [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9269 - 9272

24
[ 13139-12-3 ]
[ 96758-75-7 ]

Reference： [1]Journal of Organic Chemistry,1985,vol. 50,p. 2660 - 2664

25
[ 13139-12-3 ]
[ 706820-74-8 ]
[ 77004-72-9 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In DMF (N,N-dimethyl-formamide);	2-AMINO-6-BENZYLOXYCARBONYLAMINO-HEXANOATE (1.0 g, 2.68 mmol) was dissolved in N, N-DIMETHYLFORMAMIDE (50 mL) and then triethylamine (5.35 mmol, 0.75 ML) followed by N-(tert-butoxycarbonyloxy) succinimide (0.72 g, 3. 35 mmol) was added to the solution. The mixture was stirred overnight and then concentrated. The product was purified from the residue by silica gel chromatography (20% MEOH/CHLOROFORM) to give tert-butyl 6-BENZYLOXYCARBONYLAMINO-2-TERT-BUTOXYCARBONYLAMINO-HEXANOATE. The tri- protected product was reduced on a Parr hydrogenator (50 psi) to remove the benzyloxycarbonyl protecting group. The solvents were removed to give tert-butyl 6- amino-2-tert-butoxycarbonylamino-hexanoate (0.65 g, 80%)

Reference： [1]Patent: WO2004/50637,2004,A2 .Location in patent: Page 68

26
[ 13139-12-3 ]
[ 107885-67-6 ]
[ 625471-04-7 ]

Yield	Reaction Conditions	Operation in experiment
54%	In dichloromethane; at -78 - 20℃; for 4.16667 - 4.25h;	Example 26 2-R (AMINOCARBONYL) AMINOL-N-R (3S)-AZEPAN-3-VLL-5-(4-METHOXD7PHENVL) THIOPHENE-3 carboxamide hydrochloride (S)-3-AMINO-AZEPANE-1-CARBOXYLIC acid tert-butyl ester. (S)-Azepan-3-ylamine (5g ; 43.8 mmol) was dissolved in 100 mL of anhydrous CH2C12 and cooled to-78 C while stirring with a magnetic stirring bar. In another flask N-(TERT-BUTOXYCARBONYLOXY) SUCCINIMIDE [BOC-OSU] (9.7 g; 45 mmol) was dissolved in 50 ML of anhydrous CH2C12. To the stirred solution of the amine was added the solution of the SUCCINIMIDE over a period of 10-15 minutes so as to keep the reaction mixture at-78 C while stirring. After the addition was complete, the reaction was allowed to warm to room temperature and then stirred for an additional 4h or until the reaction was complete by TLC (Ninhydrin; Rf 0.3 ; 0.1 : 1: 10 NH4OH, MeOH ; CH2C12). The reaction mixture was washed with 50 mL of H20. The aqueous layer was brought to a pH >13 by the addition of 6N NAOH and extracted with CH2C12 (3 x 100 mL). The organic layer was dried over Na2C03, filtered, and concentracted in a vacuum to yield pure (S)-3-AMINO-AZEPANE-L-CARBOXYLIC acid tert- butyl ester as a viscous oil (5.1 g, 54%).
54%	In dichloromethane; at -78℃; for 4.16667 - 4.25h;	tert-butyl (3S)-3-aminoazepane-1-carboxylate.; (3S)-azepan-3-amine (5g ; 43.8 mmol) was dissolved in 100 mL of anhydrous CH2Cl2 and cooled to-78 C while stirring with a magnetic stirring bar. In another flask N- (tert-Butoxycarbonyloxy) succinimide [Boc-OSu] (9.7g ; 45 mmol) was dissolved in 50 mL of anhydrous CH2Cl2. To the stirred solution of the amine was added the solution of the succinimide over a period of 10-15 minutes so as to keep the reaction mixture at-78 C while stirring. After the addition was complete, the reaction was allowed to warm to room temperature and then stirred for an additional 4h or until the reaction was complete by TLC (Ninhydrin; Rf 0. 3; 0.1 : 1 : 10 NH40H, MeOH ; CH2C12). The reaction mixture was washed with 50 mL of H20. The aqueous layer was brought to a pH >13 by the addition of 6N NaOH and extracted with CH2Cl2 (3 x 100mL). The organic layer was dried over Na2C03, filtered, and concentrated in vacuo to yield pure title compound as a viscous oil (5. 1g, 54%). 1H NMR (d6-DMSO, d 3.4, m, 2H; d 2.89, m, 1H; d 2.71, m, 1H ; d 2.54, m, 1H; d 1.54, m, 3H; d 1.34, m, 3H ; d 1.27, s, 9H; d 1.12, m, 2H), LC/MS (APCI, ES, M+H=215).

Reference： [1]Patent: WO2005/16909,2005,A1 .Location in patent: Page/Page column 68
[2]Patent: WO2005/66163,2005,A2 .Location in patent: Page/Page column 55-26

27
active charcoal [ No CAS ]
[ 13139-12-3 ]
[ 6187-87-7 ]
tert.-butyl 7-(tert.-butoxycarbonylamino)-cephalosporanate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; In pyridine; water;	EXAMPLE 20 The 1,1-dioxide of tert.-butyl 7-(tert.-butoxycarbonylamino)cephalosporanate Stage 1: 4.5 g (0.021 mole) of N-(tert.-butoxycarbonyloxy)succinimide are added to 6.6 g (0.02 mole) of tert.-butyl 7-aminocephalosporanate, dissolved in 25 ccs of pyridine. The mixture is stirred at room temperature for 7 hours, the pyridine is stripped off in vacuo and the residue is triturated in water with the addition of 2 N HCl and filtered off. 8.4 g of crude product are obtained which, after recrystallization from methanol/H2 O with the addition of active charcoal, gives 6.5 g of tert.-butyl 7-(tert.-butoxycarbonylamino)-cephalosporanate of melting point 145-146.

Reference： [1]Patent: US4399131,1983,A

28
[ 13139-12-3 ]
Fmoc-Lys-Arg-Leu-Gln-Gly-Thr-Val-Pro-Ser-Leu-Asn-Leu-Val-Leu-Gln-Lys-Lys-Met-Tyr-Ser-Asn-Pro-Gln-Gln-Gln-Asn-OH [ No CAS ]
Fmoc-Lys(Boc)-Arg-Leu-Gln-Gly-Thr-Val-Pro-Ser-Leu-Asn-Leu-Val-Leu-Gln-Lys(Boc)-Lys(Boc)-Met-Tyr-Ser-Asn-Pro-Gln-Gln-Gln-Asn-OH [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2008,vol. 6,p. 1808 - 1813

29
[ 13139-12-3 ]
H-Leu-Pro-Leu-Pro-Ser-Ser-Thr-Ser-Cys(Acm)-Cys(Acm)-Thr-Gln-Leu-Tyr-Arg-Gln-Pro-Leu-Pro-Ser-Arg-Leu-Leu-Arg-Arg-Ile-Val-His-Met-Glu-Leu-Gln-Glu-Ala-Asp-Gly-S-CH₂CH₂CO-Leu-NH₂ [ No CAS ]
Boc-Leu-Pro-Leu-Pro-Ser-Ser-Thr-Ser-Cys(Acm)-Cys(Acm)-Thr-Gln-Leu-Tyr-Arg-Gln-Pro-Leu-Pro-Ser-Arg-Leu-Leu-Arg-Arg-Ile-Val-His-Met-Glu-Leu-Gln-Glu-Ala-Asp-Gly-S-CH₂CH₂CO-Leu-NH₂ [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2008,vol. 6,p. 1808 - 1813

30
[ 13139-12-3 ]
C₅₈H₉₆N₂₀O₁₄S₂ [ No CAS ]
C₇₃H₁₂₀N₂₀O₂₀S₂ [ No CAS ]

Reference： [1]Bulletin of the Chemical Society of Japan,2013,vol. 86,p. 690 - 697

31
[ 13139-12-3 ]
Fmoc-Gly-Thr-Val-Ala-Leu-Arg-Leu-Gln-Glu-Ala-Cys(SMe)-Glu-Ala-Tyr-Leu-Val-Gly-Leu-Phe-Lys-NH₂ [ No CAS ]
Fmoc-Gly-Thr-Val-Ala-Leu-Arg-Leu-Gln-Glu-Ala-Cys(SMe)-Glu-Ala-Tyr-Leu-Val-Gly-Leu-Phe-Lys(Boc)-NH₂ [ No CAS ]

Reference： [1]Bulletin of the Chemical Society of Japan,2013,vol. 86,p. 690 - 697

32
[ 13139-12-3 ]
[ 1443526-28-0 ]
Fmoc-Daa [ No CAS ]

Reference： [1]Tetrahedron,2013,vol. 69,p. 6170 - 6175

33
[ 13139-12-3 ]
[ 1417729-26-0 ]
[ 1417729-28-2 ]

Yield	Reaction Conditions	Operation in experiment
72%	In dichloromethane; at 20℃; for 24h;Inert atmosphere;	N-(tert-Butoxycarbonyloxy)succinimide (36 mg, 0.15 mmol) was added to a solution of diprotected macrocycle 28a (50 mg, 0.1 mmol) in dichloromethane (7 mL). The solution was stirred at room temperature under an inert atmosphere. The reaction progress was monitored by TLC. After 24 hours, the reaction was complete. The solution was washed directly with saturated aqueous sodium chloride solution (3×10 mL). The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by chromatography on a column of alumina (dichloromethane/methanol 90:10 to 70:30 in 5% increments) to give the desired compound 29a in the form of a brown oil (44 mg, 72%). 1H NMR (400 MHz, CDCl3) delta: 7.30-7.19 (m, 4H), 6.88-6.83 (m, 4H), 5.06-4.92 (m, 4H), 3.77 (s, 6H), 3.46-3.39 (m, 12H), 1.55 (s, 9H). 13C NMR (100 MHz, CDCl3) delta: 159.65; 156.56; 155.76; 130.04; 128.98; 114.00; 80.01; 67.15; 55.38; 49.74; 49.64; 49.47; 49.37; 49.12; 48.92; 48.80; 28.53; 27.75; 25.60. HMRS (ESI) calculated for C29H39N3O8 [M+H+], m/z 558.2815. found: 558.2808.
72%	In dichloromethane; at 20℃; for 24h;Inert atmosphere;	N-(tert-Butoxycarbonyloxy)succinimide (Boc-OSu) (36 mg, 0.15 mmol) was added to a solution of diprotected macrocycle 5 (50 mg, 0.1 mmol) in dichloromethane (7 mL). The solution was stirred at room temperature under inert atmosphere. The progress of the reaction was monitored by TLC. After 24 h, reaction was complete. The solution was washed directly with water saturated with sodium chloride (3×10 mL). The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by alumina column chromatography (dichloromethane/methanol 90:10 to 70:30 in increments of 5%) to give compound 6 in the form of a brown-colored oil (44 mg, 72%). 1H NMR (400 MHz, CDCl3) delta: 7.30-7.19 (m, 4H), 6.88-6.83 (m, 4H), 5.06-4.92 (m, 4H), 3.77 (s, 6H), 3.46-3.39 (m, 12H), 1.55 (s, 9H). 13C NMR (100 MHz, CDCl3) delta: 159.65, 156.56, 155.76, 130.04, 128.98, 114.00, 80.01, 67.15, 55.38, 49.74, 49.64, 49.47, 49.37, 49.12, 48.92, 48.80, 28.53, 27.75, 25.60. HRMS (ESI+) calculated for C29H39N3O8 [M+H]+, m/z 558.2815. found: 558.2808. Rf=0.28 (silica; cyclohexane-ethyl acetate 50:50).

Reference： [1]Patent: US2014/336373,2014,A1 .Location in patent: Paragraph 0232
[2]Patent: US2015/361116,2015,A1 .Location in patent: Paragraph 0138
[3]Chemistry - A European Journal,2013,vol. 19,p. 9511 - 9517

34
[ 13139-12-3 ]
di-tert-butyl (4-((3R,4S,5S)-3-((tert-butoxycarbonyl)amino)-5-methyl-4-(methylamino)piperidin-1-yl)pyridin-3-yl)iminodicarbonate [ No CAS ]
[ 108-24-7 ]
tert-butyl ((3R,4S,5S)-1-(3-aminopyridin-4-yl)-5-methyl-4-(N-methylacetamido)piperidin-3-yl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%		Synthesis oftert-butyl ((3R.4S.5S -l-(3-aminopyridin-4-vn-5-methyl-4-(N- methylacetamido)piperidin-3-yl)carbamate To a solution of di-tert-butyl 4-((3R,4S,5S)-3-(tert-butoxycarbonylamino)-5- methyl-4-(methylamino)piperidin-l-yl)pyridin-3-yliminodicarbonate (1.0 equiv.) in DCM (0.10 M) was added DIEA (3.0 equiv.) the reaction mixture was then cooled to 0 C. To this solution was added acetic anhydride (1.2 equiv.). The resulting mixture was at RT for 50 min. The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vacuo. 4 M HC1 (43.0 equiv.) in Dioxane was added to the residue. After lhr, the volatile was removed in vacuo. To the solution of the residue in DCM (0.10 M) at 0 C was added DIEA (3.0 equiv.) and BocOSu (1.0 equiv.). After 60 min at rt, The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was seperated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo to yield a yellow residue, which was purified by Si02 chromatography to yield tert-butyl ((3R,4S,5S)-l-(3- aminopyridin-4-yl)-5-methyl-4-(N-methylacetamido)piperidin-3-yl)carbamate in 60% yield. LC/MS (m/z) = 378.2 (MH+), R, = 0.50 min. 1HNMR (400 MHz, <cdcl3>) delta ppm 1.06 (d, J=7.83 Hz, 3 H), 1.39 - 1.50 (m, 9 H), 2.20 (br. s., 3 H), 2.34 - 2.48 (m, 1 H), 2.84 - 3.28 (m, 6 H), 3.77(d, J=18.00 Hz, 2 H), 4.19 - 4.62 (m, 1 H), 6.82 (d, J=5.09 Hz, 1 H), 7.97 (br. s., 1 H), 8.05 (br. s., 1 H).

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 159-160

35
[ 142-08-5 ]
[ 13139-12-3 ]
(±)-(1R,2R,4R,6S)-2-(tert-butoxycarbonylamino)-4-(3-(tert-butoxycarbonylamino)pyridin-4-yl)-6-methylcyclohexyl methanesulfonate [ No CAS ]
tert-butyl ((1R,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(2-oxopyridin-1(2H)-yl)cyclohexyl)carbamate [ No CAS ]
tert-butyl ((1S,2R,3R,5S)-5-(3-aminopyridin-4-yl)-3-methyl-2-(2-oxopyridin-1(2H)-yl)cyclohexyl)carbamate [ No CAS ]
tert-butyl ((1R,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(pyridin-2-yloxy)cyclohexyl)carbamate [ No CAS ]
tert-butyl ((1S,2R,3R,5S)-5-(3-aminopyridin-4-yl)-3-methyl-2-(pyridin-2-yloxy)cyclohexyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
8%; 9%; 14%; 15%		Synthesis of tert-butyl ((lR,2S.3S.5R -5-(3-aminopyridin-4-vn-3-methyl-2-(2- oxopyridin-l(2H)-yl)cyclohexyl)carbamate, tert-butyl ((l S,2R,3R,5S)-5-(3- aminopyridin-4-yl)-3-methyl-2-(2-oxopyridin- 1 (2H)-yl)cyclohexyl)carbamate, tert-butyl ((lR,2S,3S,5R -5-(3-aminopyridin-4-vn-3-methyl-2-(pyridin-2- yloxy)cyclohexyl)carbamate and tert-butyl ((l S,2R,3R,5S)-5-(3-aminopyridin-4-yl)-3- methyl-2-(pyridin-2-yloxy)cyclohexyl)carbamate Single Enantiomer Single Enantiomer Single Enantiomer Single Enantiomer To a solution of (lR,2R,4R,6S)-2-(tert-butoxycarbonylamino)-4-(3-(tert- butoxycarbonylamino)pyridin-4-yl)-6-methylcyclohexyl methanesulfonate (1.0 equiv.) CS2CO3 (3.0 equiv.) in DMF (0.15 M) was added pyridin-2-ol (1.0 equiv). The mixture was stirred at 70 C for 5 hrs. The reaction was worked up with EtOAc and Brine. The organic layer was concentrated and was treated with 4N HCl (30.0 equiv.) in Dioxane for 2 hrs at which time the volatiles were removed in vacuo. The redisue was dissolved in THF (0.15 M) and tert-butyl 2,5-dioxopyrrolidin-l-yl carbonate (1.5 equiv.) was added, followed by DIEA (3.0 equiv.). After stirring at rt for 3 hrs, the reaction was quenched with sat. NaHC03 and extracted with EtOAc. The organic layer was washed with Brine, dried over Na2S04 and concentrated. The crude was purified by prep HPLC to yield two major peaks. The fractions of the first product peak was combined and neutralized with sat. NaHC03 and extrtcted with EtOAc. The organic layer was washed with Brine, dried over Na2S04 and concentrated. Purification was completed via SFC (20% (MeOH with 10% DEA), 100 mL/min, AD column) to yield tert-butyl ((lR,2S,3S,5R)-5-(3- aminopyridin-4-yl)-3-methyl-2-(2-oxopyridin-l(2H)-yl)cyclohexyl)carbamate (8% yield, 99%ee) and tert-butyl ((lS,2R,3R,5S)-5-(3-aminopyridin-4-yl)-3-methyl-2-(2- oxopyridin-l(2H)-yl)cyclohexyl)carbamate (9% yield, 99%ee). LC/MS (m/z) = 399.2 (MH+), R, = 0.60 min. 1H NMR (400 MHz, <dmso>) delta ppm 0.72 (s, 3 H), 1.30 (s, 9 H), 1.63 - 1.81 (m, 2 H), 1.89 - 2.00 (m, 2 H), 2.02 - 2.18 (m, 2 H), 3.04 - 3.13 (m, 1 H), 4.03 - 4.12 (m, 1 H), 4.91 - 5.02 (m, 1 H), 5.04 - 5.13 (m, 2 H), 6.17 - 6.26 (m, 1 H), 6.31 - 6.41 (m, 1 H), 6.98 - 7.07 (m, 1 H), 7.32 - 7.41 (m, 2 H), 7.68 - 7.74 (m, 1 H), 7.74 - 7.82 (m, 1 H), 7.85 - 7.90 (m, 1 H). The fractions of the second product peak was combined and neutralized with sat. NaHC03 and extrtcted with EtOAc. The organic layer was washed with Brine, dried over Na2S04 and concentrated. Purification was completed via SFC (20% (MeOH with 10% DEA), 100 mL/min, AD column) to yield tert-butyl ((lR,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(pyridin-2- yloxy)cyclohexyl)carbamate (14% yield, 99%ee) and tert-butyl ((lS,2R,3R,5S)-5-(3- aminopyridin-4-yl)-3-methyl-2-(pyridin-2-yloxy)cyclohexyl)carbamate (15% yield, 99%ee). LC/MS (m/z) = 399.2 (MH+), R, = 0.65 min. 1H NMR (400 MHz, <cdcl3>) delta ppm 0.95 (d, J=6.65 Hz, 3 H), 1.35 - 1.78 (m, 12 H), 1.97 - 2.08 (m, 2 H), 2.76 (t, J=1 1.93 Hz, 1 H), 3.72 (br. s., 2 H), 3.88 (d, J=4.70 Hz, 1 H), 5.43 (d, J=7.43 Hz, 1 H), 5.59 (br. s., 1 H), 6.79 - 6.94 (m, 2 H), 7.08 (d, J=5.09 Hz, 1 H), 7.56 - 7.65 (m, 1 H), 7.98 - 8.17 (m, 3 H).

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 116-118

36
[ 13139-12-3 ]
C₁₃H₂₁N₃O₂S [ No CAS ]
(±)-tert-butyl ((1R,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(methylsulfonyl)cyclohexyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate; In 1,4-dioxane; water; for 3h;	Synthesis of (+/- tert-butyl (Y lR,2S,3S,5R -5-(3-aminopyridin-4-vn-3-methyl-2- (methylsulfonvOcyclohexyOcarbamate To a solution of (+/-)S-((lS,2R,4R,6S)-2-((tert-butoxycarbonyl)amino)-4-(3-((tert- butoxycarbonyl)amino)pyridin-4-yl)-6-methylcyclohexyl) ethanethioate (1.0 equiv.) in MeOH (0.09 M) was added potassium carbonate (3.0 equiv.). The mixture was stirred for 15 minutes at which time methyl iodide (1.1 eq.) was added and the solution was stirred at rt for 15 minutes. The volatiles were removed in vacuo and the residue was partitioned between EtOAc and H20. The organic layer was washed with H20, NaCl(sa ), dried over MgS04, filtered, concentrated and purified by ISCO Si02 chromatography to yield the methyl sulfide product in 99% yield. LC/MS (m/z) = 452.3 (MH+), R, = 0.87 min. To a solution of methyl sulfide (1.0 eq.) in THF (0.05 M) at rt was added an aqueous solution of oxone (2.2 eq.) dropwise over 10 minutes. After stirring at rt for 1 hour the solution was partitioned between EtOAc and H20. The organic layer was washed with H20, NaCl(sat.), dried over MgS04, filtered, concentrated to yield the bis Boc protected methyl sulfone product in 95% yield. LC/MS (m/z) = 484.2 (MH+), R, = 0.77 min. The bis boc procteced cyclohexyl sulfone (1.0 equiv) was treated with 4M HC1 in dioxane for 3 hours to removed both Boc groups. Upon removal of the volatiles in vacuo, the residue was suspended in 1 : 1 dioxane/Na2C03 (sat.) and N-(tert- Butoxycarbonyloxy)succinimide (1.2 eq.) was added. After stirring for 1 hour, additional N-(tert-Butoxycarbonyloxy)succinimide (1.2 eq.) was added. After stirring for an additional 2 hours the solution was extracted with CH2C12, the combined organic layers were washed with H20, NaCl(sa ), dried over MgS04, filtered, concentrated and purified by ISCO Si02 chromatography to yield the (+/-)tert-butyl ((lR,2S,3S,5R)-5-(3- aminopyridin-4-yl)-3-methyl-2-(methylsulfonyl)cyclohexyl)carbamate in 56% yield. LC/MS (m/z) = 384.3 (MH+), R, = 0.57 min. Chiral purification was completed via SFC (20% EtOH/80% n-heptanes, 20 mL/min, OJ column) to isolate the pure enantiomers. The second peak correlated with tert-butyl ((lR,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3- methyl-2-(methylsulfonyl)cyclohexyl)carbamate.

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 112-113

37
[ 13139-12-3 ]
(±)-tert-butyl ((1R,2S,3S,5R)-5-(3-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-methyl-2-(methylamino)cyclohexyl)carbamate [ No CAS ]
[ 79-22-1 ]
(±)-methyl ((1S,2R,4R,6S)-4-(3-aminopyridin-4-yl)-2-((tert-butoxycarbonyl)amino)-6-methylcyclohexyl)(methyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
20%		Synthesis of (+/-)-methyl (Yl S.2R.4R.6S)-4-(3-aniinopyridin-4-yl)-2-((tert- butoxycarbonyl)amino)-6-methylcyclohexyl)(methyl)carbamate To a solution of (+/-)-tert-butyl ((lR,2S,3S,5R)-5-(3-((tert- butoxycarbonyl)amino)pyridin-4-yl)-3-methyl-2-(methylamino)cyclohexyl)carbamate (1.0 equiv.) in DCM (0.05 M) at 0 C was added DIEA (3.0 equiv.) and then methyl chloroformate (1.5 equiv.). The homogeneous solution was left standing at 0 C at for 4 hrs. The reaction was quenched partitioned between NaHC03 solution and EtOAc. The organic layer was washed with Brine, dried over Na2S04, concentrated and purified by ISCO chromatography. The product was treated with 4 M HCl in dioxane (30.0 equiv.) at rt for 1 hour. The volatiles were removed in vacuo and the solid was pumped on for 5 minutes on the high vac. To the residue was added CH2CI2 (0.15 M DIEA (5.0 equiv.) and tert-butyl 2,5-dioxopyrrolidin-l-yl carbonate (1.6 equiv.). The solution was left stirring at rt for 1 hr. The volatiles were removed in vacuo and the residue was partitioned between EtOAc and H20. The organic layer was washed with Na2C03(sat.)? NaCl(sat), dried over MgSC^, filtered, concentrated and purified by ISCO Si02 chromatography to yield (+/-)-methyl ((lS,2R,4R,6S)-4-(3-aminopyridin-4-yl)-2-((tert- butoxycarbonyl)amino)-6-methylcyclohexyl)(methyl)carbamate in 20% yield. LC/MS (m/z) = 393.2 (MH+), R, = 0.60 min.

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 149-150

38
[ 13139-12-3 ]
di-tert-butyl (4-((3R,4S,5S)-3-((tert-butoxycarbonyl)amino)-5-methyl-4-(methylamino)piperidin-1-yl)pyridin-3-yl)iminodicarbonate [ No CAS ]
[ 79-22-1 ]
methyl ((3R,4S,5S)-1-(3-aminopyridin-4-yl)-3-((tert-butoxycarbonyl)amino)-5-methylpiperidin-4-yl)(methyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
44%		Synthesis of methyl ((3R.4S.5S -l-(3-aminopyridin-4-vn-3-((tert- butoxycarbonyl)amino)-5-methylpiperidin-4-yl)(methyl)carbamate To a solution of di-tert-butyl 4-((3R,4S,5S)-3-(tert-butoxycarbonylamino)-5- methyl-4-(methylamino)piperidin-l-yl)pyridin-3-yliminodicarbonate (1.0 equiv.) in DCM (0.10 M) was added DIEA (3.0 equiv.) the reaction mixture was then cooled to 0 C. To this solution was added methyl chloroformate (1.2 equiv.). The resulting mixture was at RT for 50 min. The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo. 4 M HC1 (43.0 equiv.) in dioxane was added to the residue. After lhr, the volatile was removed in vacuo. To the solution of the residue in DCM (0.10 M) at 0 C was added DIEA (3.0 equiv.) and BocOSu (1.0 equiv.). After 60 min at rt, The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo to yield a yellow residue, which was purified by ISCO Si02 chromatography to yield methyl ((3R,4S,5S)- 1 -(3-aminopyridin-4-yl)-3-((tert-butoxycarbonyl)amino)-5- methylpiperidin-4-yl)(methyl)carbamate in 44 % yield. LC/MS (m/z) = 394.2 (MH+), R, = 0.59 min. 1H NMR (400 MHz, <cdcl3>) delta ppm 1.06 (d, J=7.04 Hz, 3 H), 1.40 - 1.52 (m, 10 H), 2.28 - 2.42 (m, 1 H), 2.89 (d, J=4.70 Hz, 2 H), 3.08 (dd, J=11.93 Hz, 4.50 Hz, 1 H), 3.15 (s, 3 H), 3.47 (dd, J=11.15, 4.11 Hz, 1 H), 3.67 - 3.79 (m, 5 H), 4.13 - 4.23 (m, 1 H), 4.56 - 4.77 (m, 1 H), 6.80 (d, J=5.09 Hz, 1 H), 7.97 (d, J=5.48 Hz, 1 H), 8.04 (s, 1 H).

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 158-159

39
[ 13139-12-3 ]
tert-butyl ((3S,4S,5R)-1-(3-((tert-butoxycarbonyl)amino)pyridin-4-yl)-4-cyano-5-methylpiperidin-3-yl)carbamate [ No CAS ]
tert-butyl (3S,4S,5R)-1-(3-aminopyridin-4-yl)-4-cyano-5-methylpiperidin-3-ylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%		Synthesis of tert-butyl (3S,4S,5R)-l-(3-aminopyridin-4-yl)-4-cyano-5-methylpiperidin-3- ylcarbamate Tert-butyl ((3S,4S,5R)-l-(3-((tert-butoxycarbonyl)amino)pyridin-4-yl)-4-cyano- 5-methylpiperidin-3-yl)carbamate (1.0 equiv.) was treated with 4 M HC1 in dioxane (30.0 equiv.) at rt for 1 hour. The volatiles were removed in vacuo and the solid was pumped on for 5 minutes on the high vac. To the residue was added CH2C12 (0.05 M), DIEA (5.0 equiv.) and Boc-OSu (1.6 equiv.). The solution was left stirring at rt for 1 hr. The volatiles were removed in vacuo and the residue was partitioned between EtOAc and H20. The organic layer was washed with Na2C03(sat.)? NaCl(sat), dried over MgSC^, filtered, concentrated to yield tert-butyl (3S,4S,5R)-l-(3-aminopyridin-4-yl)-4-cyano-5- methylpiperidin-3-ylcarbamate in 100% yield. LC/MS (m/z) = 332.1 (MH+), R, = 0.59 mm.

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 154

40
[ 13139-12-3 ]
tert-butyl tert-butoxycarbonyl(4-((3R,4S,5S)-3-((tert-butoxycarbonyl)amino)-4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-5-methylpiperidin-1-yl)pyridin-3-yl)carbamate [ No CAS ]
tert-butyl (3R,4S,5S)-1-(3-aminopyridin-4-yl)-4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-5-methylpiperidin-3-ylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
57%		Synthesis of tert-butyl (3R,4S,5S)-l-(3-aminopyridin-4-yl)-4-(4-(hvdroxymethyl)- 1H- 1 ,2,3-triazol- 1 -yl)-5-methylpiperidin-3-ylcarbamate To di-tert-butyl 4-((3R,4S,5S)-3-(tert-butoxycarbonylamino)-4-(4- (hydroxymethyl)- 1 H- 1 ,2,3-triazol- 1 -yl)-5 -methylpiperidin- 1 -yl)pyridin-3 - yliminodicarbonate (1.0 equiv.) was added 4 M HC1 (30.0 equiv.) in dioxane. After lhr, the volatile was removed in vacuo. To the solution of the residue in DCM (0.10 M) at 0 C was added DIEA (30.0 equiv.) and BocOSu (1.0 equiv.). After 4 hrs at rt, the reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was seperated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vacuo to yield a yellow residue, which was purified by ISCO Si02 chromatography to yield tert-butyl (3R,4S,5S)-l-(3-aminopyridin-4-yl)-4-(4- (hydroxymethyl)-lH-l,2,3-triazol-l-yl)-5-methylpiperidin-3-ylcarbamate in 57% yield. LC/MS (m/z) = 404.3 (MH+), R, = 0.47 min.

Reference： [1]Patent: WO2013/175388,2013,A1 .Location in patent: Page/Page column 161-162

41
[ 13139-12-3 ]
(R)-(+)-3-Amino-hexahydro-1H-azepin [ No CAS ]
(R)-tert-butyl 3-aminoazepane-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; at -78 - 20℃;	Step C: To a solution of I-lb (32.83 g, 0.288 mol) in CH2C12 (1300 mL) at -78C was added dropwise a solution of BocOSu (51.13 g, 1.345 mol) in CH2C12 (400 mL). The mixture was stirred at room temperature overnight, treated with H20 (400 mL) and the organic phase was separated and discarded. The aqueous layer was basified to pH-13with solid NaOH and extracted with CH2C12. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford the title compound (Intermediate 1) as a yellow oil. 1H-NMR (400 MHz, CDC13): 3.74-3.42 (m, 2H), 3.28-3.18 (m, 1H), 3.11-3.01 (m, 1H), 2.97-2.88 (m, 1H), 1.88-1.50 (m, 4H), 1.48 (s, 9H),1.45-1.23 (m, 4H); MS calculated for C11H23N202 (M+H) 215.17, found 215.1.

Reference： [1]Patent: WO2013/184757,2013,A1 .Location in patent: Page/Page column 78

42
[ 13139-12-3 ]
[(Boc)Cys(S-acetamidomethyl)]TGWMAGIOGHOGHNGAOGRDGRDGTPG-COSCH₂CH₂CO(R)₃ [ No CAS ]
[(Fmoc)E]K(glucosylgalactosyl hydroxy)K(glucosylgalactosyl hydroxy)GEK(glucosylgalactosyl hydroxy)GDPGLIGPK(glucosylgalactosyl hydroxy)GDIGETGVPG-3-(tert-butyldisulfanyl)-2-(ethylamino)propanamide [ No CAS ]
[ 107-96-0 ]
[Cys(S-acetamidomethyl)]TGWMAGIOGHOGHNGAOGRDGRDGTPGEK(glucosylgalactosyl hydroxy)GEK(glucosylgalactosyl hydroxy)GDPGLIGPK(glucosylgalactosyl hydroxy)GDIGETGVPG-COSCH₂CH₂CO₂H [ No CAS ]

Reference： [1]Tetrahedron Letters,2014,vol. 55,p. 3073 - 3076

43
[ 13139-12-3 ]
C₁₃H₂₁N₃O₂S*2ClH [ No CAS ]
(±)-tert-butyl ((1R,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(methylsulfonyl)cyclohexyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate; In 1,4-dioxane; for 3h;	Synthesis of (+/-)-tert-butyl ((1R,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3-methyl-2-(methylsulfonyl)cyclohexyl)carbamate To a solution of (+/-)S-((lS,2R,4R,6S)-2-((tert-butoxycarbonyl)amino)-4-(3-((tert- butoxycarbonyl)amino)pyridin-4-yl)-6-methylcyclohexyl) ethanethioate (1.0 equiv.) in MeOH (0.09 M) was added potassium carbonate (3.0 equiv.). The mixture was stirred for 15 minutes at which time methyl iodide (1.1 eq.) was added and the solution was stirred at rt for 15 minutes. The volatiles were removed in vacuo and the residue was partitioned between EtOAc and H20. The organic layer was washed with H20, NaCl(sat.), dried over MgS04, filtered, concentrated and purified by ISCO Si02 chromatography to yield the methyl sulfide product in 99% yield. LC/MS (m/z) = 452.3 (MH+), R, = 0.87 min. To a solution of methyl sulfide (1.0 eq.) in THF (0.05 M) at rt was added an aqueous solution of oxone (2.2 eq.) dropwise over 10 minutes. After stirring at rt for 1 hour the solution was partitioned between EtOAc and H20. The organic layer was washed with H20, NaCl(sat), dried over MgS04, filtered, concentrated to yield the bis Boc protected methyl sulfone product in 95% yield. LC/MS (m/z) = 484.2 (MH+), R, = 0.77 min. The bis boc procteced cyclohexyl sulfone (1.0 equiv) was treated with 4M HC1 in dioxane for 3 hours to removed both Boc groups. Upon removal of the volatiles in vacuo, the residue was suspended in 1 : 1 dioxane/Na2C03 (sat.) and N-(tert- Butoxycarbonyloxy)succinimide (1.2 eq.) was added. After stirring for 1 hour, additional N-(tert-Butoxycarbonyloxy)succinimide (1.2 eq.) was added. After stirring for an additional 2 hours the solution was extracted with CH2C12, the combined organic layers were washed with H20, NaCl(sa ), dried over MgS04, filtered, concentrated and purified by ISCO Si02 chromatography to yield the (+/-)tert-butyl ((lR,2S,3S,5R)-5-(3- aminopyridin-4-yl)-3-methyl-2-(methylsulfonyl)cyclohexyl)carbamate in 56% yield. LC/MS (m/z) = 384.3 (MH+), R, = 0.57 min. Chiral purification was completed via SFC (20% EtOH/80% n-heptanes, 20 mL/min, OJ column) to isolate the pure enantiomers. The second peak correlated with tert-butyl ((lR,2S,3S,5R)-5-(3-aminopyridin-4-yl)-3- methyl-2-(methylsulfonyl)cyclohexyl)carbamate.

Reference： [1]Patent: WO2014/99880,2014,A1 .Location in patent: Page/Page column 130; 131

44
[ 13139-12-3 ]
C₁₅H₂₄N₄O₂*2ClH [ No CAS ]
(±)-methyl ((1S,2R,4R,6S)-4-(3-aminopyridin-4-yl)-2-((tert-butoxycarbonyl)amino)-6-methylcyclohexyl)(methyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 1h;	Synthesis of (+/- -methyl ( ( 1 S.2R,4R,6SV4-(3-aminopyridin-4-yr)-2-( (tert- butoxycarbonyl)amino)-6-methylcvclohexyl)(methyl)carbamate To a solution of (+/-)-tert-butyl ((lR,2S,3S,5R)-5-(3-((tert- butoxycarbonyl)amino)pyridin-4-yl)-3-methyl-2-(methylamino)cyclohexyl)carbamate (1.0 equiv.) in DCM (0.05 M) at 0 C was added DIEA (3.0 equiv.) and then methyl chloroformate (1.5 equiv.). The homogeneous solution was left standing at 0 C at for 4 hrs. The reaction was quenched partitioned between NaHC03 solution and EtOAc. The organic layer was washed with Brine, dried over Na2S04, concentrated and purified by ISCO chromatography. The product was treated with 4 M HCl in dioxane (30.0 equiv.) at rt for 1 hour. The volatiles were removed in vacuo and the solid was pumped on for 5 minutes on the high vac. To the residue was added CH2C12 (0.15 M), DIEA (5.0 equiv.) and tert-butyl 2,5-dioxopyrrolidin-l-yl carbonate (1.6 equiv.). The solution was left stirring at rt for 1 hr. The volatiles were removed in vacuo and the residue was partitioned between EtOAc and H20. The organic layer was washed with Na2C03(sat.), NaCl(Sat), dried over MgS04, filtered, concentrated and purified by ISCO Si02 chromatography to yield (+/-)-methyl ((lS,2R,4R,6S)-4-(3-aminopyridin-4-yl)-2-((tert- butoxycarbonyl)amino)-6-methylcyclohexyl)(methyl)carbamate in 20% yield. LC/MS (m/z) = 393.2 (MH+), R, = 0.60 min.

Reference： [1]Patent: WO2014/99880,2014,A1 .Location in patent: Page/Page column 146; 147

45
[ 13139-12-3 ]
C₂₉H₄₇N₅O₈ [ No CAS ]
methyl ((3R,4S,5S)-1-(3-aminopyridin-4-yl)-3-((tert-butoxycarbonyl)amino)-5-methylpiperidin-4-yl)(methyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Synthesis of methyl ((3R.4S.5S -l-(3-aminopyridin-4-vn-3-((tert- butoxycarbonyl)amino)-5-methylpiperidin-4-yl)(methyl)carbamate To a solution of di-tert-butyl 4-((3R,4S,5S)-3-(tert-butoxycarbonylamino)-5- methyl-4-(methylamino)piperidin-l-yl)pyridin-3 -yliminodicarbonate (1.0 equiv.) in DCM (0.10 M) was added DIEA (3.0 equiv.) the reaction mixture was then cooled to 0 C. To this solution was added methyl chloro formate (1.2 equiv.). The resulting mixture was at RT for 50 min. The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo. 4 M HC1 (43.0 equiv.) in dioxane was added to the residue. After lhr, the volatile was removed in vacuo. To the solution of the residue in DCM (0.10 M) at 0 C was added DIEA (3.0 equiv.) and BocOSu (1.0 equiv.). After 60 min at rt, The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo to yield a yellow residue, which was purified by ISCO Si02 chromatography to yield methyl ((3R,4S ,5 S)- 1 -(3 -aminopyridin-4-yl)-3 -((tert-butoxycarbonyl)amino)-5 - methylpiperidin-4-yl)(methyl)carbamate in 44 % yield. LC/MS (m/z) = 394.2 (MH+), R, = 0.59 min. 1H NMR (400 MHz, <cdcl3>) delta ppm 1.06 (d, J=7.04 Hz, 3 H), 1.40 - 1.52 (m, 10 H), 2.28 - 2.42 (m, 1 H), 2.89 (d, J=4.70 Hz, 2 H), 3.08 (dd, J=1 1.93 Hz, 4.50 Hz, 1 H), 3.15 (s, 3 H), 3.47 (dd, J=1 1.15, 4.1 1 Hz, 1 H), 3.67 - 3.79 (m, 5 H), 4.13 - 4.23 (m, 1 H), 4.56 - 4.77 (m, 1 H), 6.80 (d, J=5.09 Hz, 1 H), 7.97 (d, J=5.48 Hz, 1 H), 8.04 (s, 1 H).

Reference： [1]Patent: WO2014/99880,2014,A1 .Location in patent: Page/Page column 106; 107

46
[ 13139-12-3 ]
C₂₉H₄₇N₅O₇ [ No CAS ]
tert-butyl ((3R,4S,5S)-1-(3-aminopyridin-4-yl)-5-methyl-4-(N-methylacetamido)piperidin-3-yl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Synthesis of tert-butyl (Y3R.4S.5 S 1 -(3-aminopyridin-4-ylV5-methyl-4-(N- methylacetamido)piperidin-3-yl)carbamate To a solution of di-tert-butyl 4-((3R,4S,5S)-3-(tert-butoxycarbonylamino)-5- methyl-4-(methylamino)piperidin-l-yl)pyridin-3-yliminodicarbonate (1.0 equiv.) in DCM (0.10 M) was added DIEA (3.0 equiv.) the reaction mixture was then cooled to 0 C. To this solution was added acetic anhydride (1.2 equiv.). The resulting mixture was at RT for 50 min. The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was separated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vacuo. 4 M HC1 (43.0 equiv.) in Dioxane was added to the residue. After lhr, the volatile was removed in vacuo. To the solution of the residue in DCM (0.10 M) at 0 C was added DIEA (3.0 equiv.) and BocOSu (1.0 equiv.). After 60 min at rt, The reaction mixture was quenched with NaHC03 and diluted with EtOAc. The aqeuous layer was seperated and extracted with EtOAc, the combined organics were then dried over MgS04 and concentrated in vaccuo to yield a yellow residue, which was purified by Si02 chromatography to yield tert-butyl ((3R,4S,5S)-l-(3- aminopyridin-4-yl)-5-methyl-4-(N-methylacetamido)piperidin-3-yl)carbamate in 60% yield. LC/MS (m/z) = 378.2 (MH+), R, = 0.50 min. 1HNMR (400 MHz, <cdcl3>) delta ppm 1.06 (d, J=7.83 Hz, 3 H), 1.39 - 1.50 (m, 9 H), 2.20 (br. s., 3 H), 2.34 - 2.48 (m, 1 H), 2.84 - 3.28 (m, 6 H), 3.77(d, J=18.00 Hz, 2 H), 4.19 - 4.62 (m, 1 H), 6.82 (d, J=5.09 Hz, 1 H), 7.97 (br. s., 1 H), 8.05 (br. s., 1 H).

Reference： [1]Patent: WO2014/99880,2014,A1 .Location in patent: Page/Page column 107; 108

47
[ 13139-12-3 ]
C₂₇H₃₇N₃O₆ [ No CAS ]
C₃₂H₄₅N₃O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
42%	In dichloromethane; at 20℃; for 24h;	N-(tert-Butoxycarbonyloxy)succinimide (630 mg, 2.93 mmol) was added to a solution of diMOZ macrocycle 28b (980 mg, 1.96 mmol) in dichloromethane (40 mL). The reaction mixture was stirred at room temperature for 24 hours. The reaction progress was monitored by TLC. After this period, the reaction was complete. The solution was washed with saturated aqueous sodium chloride solution (2×20 mL). The aqueous phases were combined and extracted with dichloromethane (2×30 mL). The organic phases were combined, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by chromatography on a column of alumina (cyclohexane/ethyl acetate 100:0 to 70:30 in 5% increments) to give the desired compound 29b in the form of an oil (507 mg, 42%).

Reference： [1]Patent: US2014/336373,2014,A1 .Location in patent: Paragraph 0233

48
[ 13139-12-3 ]
C₄₅H₅₆N₈O₁₀*C₂HF₃O₂ [ No CAS ]
cyclo[Phe-NMeGlu-Tyr-DTrp-Lys(Boc)-Thr] [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 4h;	S nthesis of intermediatesTo a solution of 5' trifluoroacetate salt (380 mg, 0.387 mmol) in DMF (5 mL) and diisopropylethylamine (0.50 mL) was added a solution of BocOSu (91.5 mg, 0.425 mmol) in DMF (2 mL). The reaction was stirred at room temperature for 4 h, then the reaction mixture loaded onto a 50 g C 18 Isco column. Eluting with 5% to 75% acetonitrile in water with 0.1% AcOH yielded 6' (338 mg, 0.349 mmol, 90% yield).

Reference： [1]Patent: WO2016/4048,2016,A2 .Location in patent: Paragraph 00335

49
[ 13139-12-3 ]
octreotide acetate [ No CAS ]
[ 119643-69-5 ]

Yield	Reaction Conditions	Operation in experiment
74%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at -40 - 20℃; for 2h;	Synthesis of intermediatesTo a solution of octreotide acetate (545 mg, 0.505 mmol) in DMF (10 mL) was added diisopropylethylamine (0.50 mL). The solution was then cooled to -40 C, and a solution of BocOSu (119 mg, 0.553 mmol) in DMF (5 mL) was added dropwise. The reaction was stirred at -40 C for 1 h, then gradually warmed up to room temperature over 1 h. Most of the DMF was removed in vacuo, and the remaining residue was loaded onto a 50 g C18 Isco column. Elution with 15% to 60% acetonitrile in water with 0.1% AcOH gave Lys-Boc octreotide acetate (54', 440 mg, 0.373 mmol, 74% yield) with >95% regioselectivity by XH NMR.

Reference： [1]Patent: WO2016/4048,2016,A2 .Location in patent: Paragraph 00360

50
[ 13139-12-3 ]
octreotide acetate [ No CAS ]
Lys-Boc octereotide acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
67%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at -40 - 20℃; for 3h;	EXAMPLE 1 : Synthesis of Conjugate 1To a solution of octreotide acetate (2.08 g, 1.93 mmol) in DMF (20 mL) and diisopropylethylamine (2.0 mL), cooled to -40 C, was added a solution of BocOSu (419 mg, 1.95 mmol) in DMF (5 mL) dropwise. The reaction was gradually warmed to room temperature, over 3 hours. Most of the DMF was removed, and the reaction mixture loaded onto a CI 8 column, eluting with 15% to 60% acetonitrile in water with 0.1% AcOH, to give the product as the acetate salt (1.53 g, 1.30 mmol,- Boc + 2H)/2.
67%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at -40 - 20℃; for 3h;	[00629j To a solution of octreotide acetate (2.08 g, 1.93 mmoi) in DMF (20 itT.) and diisopropyiethyianiine (2.0 niL). cooled to -40 C, was added a solution of BocOSu (419 mg, 1,95 mmol) in DMF (5 mL) dropwise. The reaction was gradually warmed to room teniperature, over 3 hours. Most of the DMF was removed, and the reaction mixture loaded onto a Cl 8 column, eluting with 15% to 60% acetonitrile it water with 0.1% AeOH, to give the product as the acetate salt (1.53 g, 1.30 mmol, 67% yield). LCMS mIz: 510.3 (M Boc f 2H)/2.

Reference： [1]Patent: WO2016/4048,2016,A2 .Location in patent: Page/Page column 00289
[2]Patent: WO2016/4043,2016,A1 .Location in patent: Paragraph 00629

51
[ 13139-12-3 ]
cyclo[Phe-NMeGlu-Tyr-DTrp-Lys(Boc)-Thr] [ No CAS ]

Reference： [1]Patent: WO2016/4048,2016,A2

52
[ 13139-12-3 ]
C₆₁H₈₀N₁₀O₁₁S₂ [ No CAS ]

Reference： [1]Patent: WO2016/4048,2016,A2

53
[ 13139-12-3 ]
[ 761001-89-2 ]
(S,E)-2-(tert-butoxycarbonylamino)-7-methoxy-7-oxohept-5-enoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%		7.0 g of (S,E)-7-tert-butyl 1-methyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate (15.8 mmol) are dissolve in 40 mL of dichloromethane and added into the solution of 70 mL of trifluoroacetic acid. It is stirred at RT for 4 h. The solvent is removed in vacuo and the green residue is dried under high vacuum. The obtained oil is further used without purification. By successive addition of DIPEA the pH value is adjusted to ca. 7. The oil is taken up in 50 mL of DMF and treated with 5.37 mL of DIPEA. 4.08 g of Boc-OSu (18.9 mmol, 1.2 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is suspended in 130 mL of 5% KHSO4 solution. It is extracted with ethyl acetate (1×150 mL, 2×100 mL) and the corrected organic phases are washed with brine (75 mL). After drying of the organic phase over Na2SO4 the solvent is removed in vacuo. The residue is purified by chromatography on silica gel (column: 13*6.0 cm, toluene/ethyl acetate 65:35, 0.5% acetic acid). Colorless oil is obtained.Column chromatography: collected in 200 mL fractions, product: fractions 2-5, first running 500 mLTLC control: toluene/ethyl acetate 1:1, 0.5% acetic acid, Rf=0.35Yield: 4.04 g, 14.1 mmol, 89% (purity 88.6%)ESI-MS: 310.1 [M+Na]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0135; 0136

54
[ 13139-12-3 ]
(S,E)-methyl 7-(1-(2-tert-butoxy-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl-amino)-6-(tert-butoxycarbonylamino)-7-oxohept-2-enoate [ No CAS ]
(S,E)-2-(3-(2-(tert-butoxycarbonylamino)-7-methoxy-7-oxohept-5-enamido)-2-oxopyridin-1(2H)-yl)acetic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
201 mg		590 mg of (S,E)-methyl 7-(1-(2-tert-butoxy-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl-amino)-6-(tert-butoxycarbonylamino)-7-oxohept-2-enoate (ZED1209, 1.20 mmol) are dissolved in 10 mL of dichloromethane and to this solution 10 mL of trifluoroacetic acid is added. It is stirred at RT for 1 h. The solvent is removed in vacuo and the residue is dried under high vacuum. The obtained oil is further reacted without purification. The oil is taken up in 15 mL of DMF and treated with 173 muL of DIPEA. By successive addition of DIPEA the pH value is adjusted to ca. 7. To this solution, 285 mg of Boc-OSu (1.1 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is purified by preparative HPLC (30% ACN in water, 8 mL/min, gradient 1% pro min).Yield: 201 mg, 0.46 mmol, 38%ESI-MS: 438.2 [M+H]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0173; 0174; 0175

55
[ 13139-12-3 ]
(S,E)-7-tert-butyl 1-ethyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate [ No CAS ]
(S,E)-2-(tert-butoxycarbonylamino)-7-ethoxy-7-oxohept-5-enoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
39%		972 mg of (S,E)-7-tert-butyl 1-ethyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate (ZED724, 2.12 mmol) are dissolve in 15 mL of dichloromethane and to this solution 15 mL of trifluoroacetic acid is added. It is stirred at RT for 2 h. The solvent is removed in vacuo and the residue is dried under high vacuum. The obtained oil is further reacted without purification.The oil is taken up in 30 mL DMF and treated with 361 muL of DIPEA. By successive addition of DIPEA the pH value is adjusted to ca. 7. 502 mg of Boc-OSu (2.33 mmol, 1.1 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is purified by chromatography on silica gel (column: 23*6.0 cm, dichloromethane/methanol 9:1). Colorless oil is obtained.Column chromatography: corrected in 50 mL fractions, product: fractions 35-80TLC control: Dichloromethane/Methanol 9:1, Rf=0.21Yield: 249 mg, 0.83 mmol, 39%ESI-MS: 302.2 [M+H]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0183; 0184; 0185

56
[ 13139-12-3 ]
C₂₄H₄₁NO₈ [ No CAS ]
(S,E)-2-(tert-butoxycarbonylamino)-7-isopropoxy-7-oxohept-5-enoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77%		518 mg of (S,E)-7-tert-butyl 1-isopropyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate (ZED855, 1.10 mmol) are dissolve in 10 mL of dichloromethane and to this solution 10 mL of trifluoroacetic acid is added. It is stirred at RT for 2 h. The solvent is removed in vacuo and the residue is dried under high vacuum. The obtained oil is further reacted without purification.The oil is taken up in 2.5 mL DMF and treated with 185 muL of DIPEA. By successive addition of DIPEA the pH value is adjusted to ca. 7. 259 mg of Boc-OSu (1.21 mmol, 1.1 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is taken up in 75 mL of ethyl acetate and washed two times with 10% citric acid and once with brine. After drying of the organic phase over Na2SO4, the solvent is removed in vacuo. The residue is purified by preparative HPLC (40% ACN in water, 8 mL/min, gradient 1% pro min).Yield: 267 mg, 0.85 mmol, 77%ESI-MS: 316.2 [M+H]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0193; 0194; 0195

57
[ 13139-12-3 ]
(S,E)-tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-6-(methylsulfonyl)hex-5-enoate [ No CAS ]
(S,E)-2-(tert-butoxycarbonylamino)-6-(methylsulfonyl)hex-5-enoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
63%		356 mg of (S,E)-tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-6-(methylsulfonyl)hex-5-enoate (ZED865, 0.77 mmol) are dissolve in 10 mL of dichloromethane and to this solution 10 mL of trifluoroacetic acid is added. It is stirred at RT for 1 h. The solvent is removed in vacuo and the residue is dried under high vacuum. The obtained oil is further reacted without purification.The oil is taken up in 5 mL of DMF and treated with 131 muL of DIPEA. By successive addition of DIPEA the pH value is adjusted to ca. 7. 182 mg of Boc-OSu (0.85 mmol, 1.1 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is purified by preparative HPLC (5% ACN in water, 8 mL/min, gradient 1% pro min).Yield: 148 mg, 0.48 mmol, 63%ESI-MS: 308.1 [M+H]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0202; 0203; 0204

58
[ 13139-12-3 ]
(S,E)-1-benzyl 7-tert-butyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate [ No CAS ]
(S,E)-7-(benzyloxy)-2-(tert-butoxycarbonylamino)-7-oxohept-5-enoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%		94 mg of (S,E)-1-benzyl 7-tert-butyl 6-(bis(tert-butoxycarbonyl)amino)hept-2-enedioate (ZED818, 0.18 mmol) are dissolve in 2 mL of dichloromethane and to this solution 2 mL of trifluoroacetic acid is added. It is stirred at RT for 1.5 h. The solvent is removed in vacuo and the residue is dried under high vacuum. The obtained oil is further reacted without purification.The oil is taken up in 2 mL DMF and treated with 61 muL of DIPEA (2 eq). By successive addition of DIPEA the pH value is adjusted to ca. 7. 43 mg of Boc-OSu (0.20 mmol, 1.1 eq) are added and stirred at RT overnight. The solvent is removed in vacuo and the residue is purified by preparative HPLC (35% ACN in water, 8 mL/min, gradient 1% pro min).Yield: 60 mg, 0.16 mmol, 91%ESI-MS: 364.1 [M+H]+

Reference： [1]Patent: JP2015/529645,2015,A .Location in patent: Paragraph 0211; 0212; 0213

59
[ 13139-12-3 ]
[ 934240-38-7 ]
1-(tert-butyl) 2-methyl (2S,5R)-5-(4-hydroxyphenyl)pyrrolidine-1,2-dicarboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.24 g	With 20% palladium hydroxide-activated charcoal; hydrogen; In methanol;	A 1 L Buchi hydrogenation reactor was charged with 20% Pd(OH)2/ C, (300 mg, 1 wt%), (S)-methyl-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate, (which may be prepared as described herein for Description 2), (30.00 g, 97.0 mmol), N-(tert- butoxycarbonyloxy)succinimide, (21.52 g, 102 mmol, 1.00 eq based on 97% purity) and methanol (360 ml_). The mixture was pressurized with hydrogen gas (4 bar), agitated at -1000 rpm and maintained at < 23 C; the reaction was sampled periodically for completion (HPLC). Upon completion, Celite (5 g) was charged to the reactor and stirring was continued for an additional 5 - 10 min. The mixture was filtered through a pad of Celite (5 g). The reactor was charged with methanol (60 ml_) and this rinse was used to wash the filter cake. One-quarter of the combined filtrate and wash was concentrated by rotary evaporation to low volume. Following charging of methanol (15 ml_), water (7.5 ml_) was added slowly over 15 - 20 min at ambient temperature with good stirring. After aging for ~ 35 min at ambient temperature, the slurry was aged at -5 C overnight, filtered, washed with cold (-5 C) 1 :4 (v/v) methanol - water (2 X 7.5 ml_) and dried to constant weight in vacuo at 35 C to afford (D3) as a crystalline solid, (6.24 g)

Reference： [1]Patent: WO2016/102967,2016,A1 .Location in patent: Page/Page column 36

60
[ 13139-12-3 ]
(2S,2aR,2a¹S,3R,4aS,6R,7aS)-2-allyl-3-[(tert-butyldimethylsilyl)oxy]-2a¹-[3-(4-methoxyphenoxy)propyl]decahydro-1H-cyclopenta[cd]indole-6-carbonitrile [ No CAS ]
tert-butyl (2S,2aR,2a¹S,3R,4aS,6R,7aS)-2-allyl-3-[(tert-butyldimethylsilyl)oxy]-6-cyano-2a¹-[3-(4-methoxyphenoxy)propyl]decahydro-1H-cyclopenta[cd]indole-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
92%	With triethylamine; In N,N-dimethyl-formamide; at 30℃; for 3h;Inert atmosphere;	To a solution of 37 (1.74 g, 3.41 mmol) and Et3N (1.43 mL, 10.2 mmol) in DMF (20.0 mL) was added <strong>[13139-12-3]N-(tert-butoxycarbonyloxy)succinimide</strong> (1.47 g, 6.82 mmol) at r.t. and the solution was heated at 40 C for 3 h. After cooling to 0 C, EtOAc and aq NaHCO3 were added. The resulting solution was extracted with EtOAc. The organic phase was washed with brine, dried (Na2SO4), and filtered. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography(SiO2; n-hexane-EtOAc, 5:1) to give 38 (1.91 g, 92%) as a white amorphous solid; [alpha]D27 +17.9 (c = 1.00, CHCl3).IR (film): 2932, 2857, 2362, 2238, 1695, 1508, 1472, 1394, 1232,1174, 1130, 1045, 884, 835, 776 cm-1.1H NMR (400 MHz, CDCl3): delta = 6.82 (s, 4 H), 5.67 (dddd, J = 18.4, 13.4,7.3, 2.3 Hz, 1 H), 5.05 (d, J = 15.6 Hz, 1 H), 5.04 (d, J = 12.4 Hz, 1 H),4.43 (ddd, J = 8.2, 4.1, 2.3 Hz, 1 H), 4.04 (ddd, J = 13.2, 8.2, 7.3 Hz, 2 H),3.91 (t, J = 6.0 Hz, 2 H), 3.76 (s, 3 H), 3.58 (dd, J = 3.2, 2.7 Hz, 1 H), 2.68 (dddd, J = 12.4, 12,4, 3.0, 3.0 Hz, 1 H), 2.36-2.20 (m, 2 H), 2.07 (dd, J =7.3, 2.3 Hz, 1 H), 2.02-1.90 (m, 2 H), 1.85-1.70 (m, 3 H), 1.69-1.54 (m,6 H), 1.47 (s, 9 H), 0.89 (s, 9 H), 0.04 (s, 3 H), 0.03 (s, 3 H).13C NMR (100 MHz, CDCl3): delta = 153.9 (C), 153.5 (C), 152.8 (C), 134.7(CH), 123.0 (C), 117.2 (CH2), 115.4 (CH), 114.6 (CH), 79.7 (C), 72.6(CH), 68.5 (CH2), 60.5 (CH), 57.0 (CH), 55.7 (CH3), 53.6 (CH), 50.2 (C),39.2 (CH2), 38.6 (CH2), 36.7 (CH), 34.8 (CH2), 29.3 (CH2), 29.0 (CH2),28.4 (CH3), 25.8 (CH2), 25.8 (CH3), 19.1 (CH), 18.0 (C), -4.6 (CH3), -4.9(CH3).HRMS (ESI+): m/z calcd for C35H54N2O5SiNa: 633.3700; found:633.3719.

Reference： [1]Synthesis,2017,vol. 49,p. 96 - 114

61
[ 13139-12-3 ]
di-tert-butyl-4-(4-(tert-butyl)benzyl)-10-(2-(3-(3-nitrophenyl)ureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate [ No CAS ]

Reference： [1]Dalton Transactions,2017,vol. 46,p. 3192 - 3206

62
[ 13139-12-3 ]
di-tert-butyl-4-(4-(tert-butyl)benzyl)-10-(2-(3-(4-hexylphenyl)ureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate [ No CAS ]

Reference： [1]Dalton Transactions,2017,vol. 46,p. 3192 - 3206

63
[ 13139-12-3 ]
di-tert-butyl-4-(2-(3-(3-nitrophenyl)ureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate [ No CAS ]

Reference： [1]Dalton Transactions,2017,vol. 46,p. 3192 - 3206

64
[ 13139-12-3 ]
di-tert-butyl-4-(2-(3-(4-hexylphenyl)ureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate [ No CAS ]

Reference： [1]Dalton Transactions,2017,vol. 46,p. 3192 - 3206

65
[ 13139-12-3 ]
[ 294-90-6 ]
[ 5437-45-6 ]
[ 913542-70-8 ]

Yield	Reaction Conditions	Operation in experiment
87%		To a solution of 1,4,7,10-tetraazacyclododecane free base 1(714 mg, 4.067 mmol) in chloroform (35 mL), N-(tert-Butoxycarbonyloxy)succinimide (8.134 mmol) was added. The reaction mixture was stirred at room temperature for 28 h. Solvent was removed by rotary evaporation and 30 mL of NaOH 3 M was added to the remaining residue. The aqueous phase was extracted with chloroform (3.3 mL). The extracts were combined and dried (over K2CO3). The solvent was removed by rotary evaporation and the residue was dried in vacuum for several hours. 513 mg of the unpurified compound from the preceding reaction (1.3761 mmol)was solubilized in acetonitrile. 0.67 mL (2.87 mmol) of benzyl bromoacetate and 0.474 g (3.412 mmol) K2CO3 were added to this solution at room temperature, after which the mixture was heated under reflux for 8 h. The solids were discarded by filtration over Celite and the solvent was removed under vacuum. Chromatographic purification (alumina, 98/2 DCM/MeOH) yielded 2 as aslowly solidifying colourless oil (736 mg, 87% over all for two steps). 1H NMR (500 MHz, CDCl3) d (ppm): 7.31 (m, 10H), 5.11 (s,4H), 3.54 (s, 4H), 3.49 (m, 8H), 2.86 (m, 8H), 1.41 (s, br 18H). 13C(500 MHz, CDCl3) d (ppm): 171.48, 157.11, 136.02, 79.33, 66.04,55.04, 54.51, 46.68, 28.46. ESI-MS (C36H52N4O8); m/z = 668 [M+H]+.

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 4297 - 4303

66
[ 13139-12-3 ]
[ 120173-56-0 ]
[ 1271737-90-6 ]

Reference： [1]Chemistry - A European Journal,2017,vol. 23,p. 9253 - 9257

67
[ 13139-12-3 ]
[ 15761-38-3 ]
[ 1271737-90-6 ]
[ 19767-45-4 ]
C₉₇H₁₆₄N₂₀O₅₀S₂ [ No CAS ]

Reference： [1]Chemistry - A European Journal,2017,vol. 23,p. 9253 - 9257

68
[ 132178-37-1 ]
[ 13139-12-3 ]
N^εB29C₁₄ RHI [ No CAS ]
N^αB1-propargyl-C₅N^εB29-C₁₄ RHI [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 19 (0780) Synthesis of NalphaB1-propargyl-C5 NepsilonB29C14 RHI (INS22). (0781) (0782) Step 1: NepsilonB29C14 RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO ( 2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for NalphaA1 Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N2 and vacuum for one hour. (0783) Step 2: TFA (15 mL, 195 mmol) is added to the above crude material (3 g, 0.493 mmol) and the reaction is stirred and sonicated until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to water (75mL) and the precipitated solids are filtered and dried under N2 and vacuum. The crude material is purified using RP- HPLC to give the NalphaB1-propargyl-C5 NepsilonB29C14 RHI

Reference： [1]Patent: WO2017/160669,2017,A1 .Location in patent: Page/Page column 111

69
[ 132178-37-1 ]
[ 13139-12-3 ]
N^εB29γE-C₁₆ RHI [ No CAS ]
N^αB1-propargyl-C₅N^εB29γE_-C₁₆ RHI [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 20 (0784) Synthesis of NalphaB1-propargyl-C5 NepsilonB29gammaE-C16 RHI (INS23). (0785) Step 1: NepsilonB29gammaE-C16 RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO ( 2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for NalphaA1 Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N2 and vacuum for one hour. (0786) Step 2: TFA (15 mL, 195 mmol) is added to the above crude material (3 g, 0.493 mmol) and the reaction is stirred and sonicated until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to water (75mL) and the precipitated solids are filtered and dried under N2 and vacuum. The crude material is purified using RP- HPLC to give the NalphaB1-propargyl-C5 NepsilonB29gammaE-C16 RHI

Reference： [1]Patent: WO2017/160669,2017,A1 .Location in patent: Page/Page column 111; 112

70
[ 13139-12-3 ]
recombinant human insulin [ No CAS ]
N^αA1N^εB29bis-Boc RHI [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 2,2,6,6-tetramethyl-piperidine; In dimethyl sulfoxide; at 20℃; for 4h;	RHI (10 g) is dissolved in DMSO (200 mL) at RT the mixture is stirred at RT until homogeneous. To the solution is added 2,2,6,6-tetramethylpiperidine (5.8 mL) followed slow addition of a solution of <strong>[13139-12-3]tert-butyl (2,5-dioxopyrrolidin-1-yl) carbonate</strong> (Boc-OSu, 0.8 g) in DMSO (10 mL). The reaction is agitated for four hours and the mixture is transferred to IPAc (1 L) over 20 minutes. The slurry is centrifuged for two hours and the solid is filtered, washed with IPAc (20ml X 3) and dried under vacuum to give bis-Boc RHI.

Reference： [1]Patent: WO2017/160669,2017,A1 .Location in patent: Page/Page column 101

71
[ 13139-12-3 ]
N^εB29γE-C₁₆ RHI [ No CAS ]
C₃₄H₅₉NO₁₇ [ No CAS ]
N^αB1-propargyl-PEG₁₃N^εB29γE_-C₁₆ RHI [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 21 (0787) Synthesis of NalphaB1-propargyl-PEG13 NepsilonB29gammaE-C16 RHI (INS24). (0788) Step 1: NepsilonB29gammaE-C16 RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO ( 2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for NalphaA1 Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N2 and vacuum for one hour. (0789) Step 2: TFA (15 mL, 195 mmol) is added to the above crude material (3 g, 0.493 mmol) and the reaction is stirred and sonicated until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to water (75mL) and the precipitated solids are filtered and dried under N2 and vacuum. The crude material is purified using RP- HPLC to give the NalphaB1-propargyl-PEG13 NepsilonB29gammaE-C16 RHI.

Reference： [1]Patent: WO2017/160669,2017,A1 .Location in patent: Page/Page column 112; 113

72
[ 13139-12-3 ]
[ 1154758-54-9 ]
[ 1154758-55-0 ]

Reference： [1]ACS Infectious Diseases,2018,vol. 4,p. 1114 - 1120

73
[ 13139-12-3 ]
[ 1007596-97-5 ]

Reference： [1]Patent: WO2008/20222,2008,A1

74
[ 13139-12-3 ]
[ 1007596-93-1 ]

Reference： [1]Patent: WO2008/20222,2008,A1

75
[ 13139-12-3 ]
[ 1007596-96-4 ]

Reference： [1]Patent: WO2008/20222,2008,A1

76
[ 13139-12-3 ]
[ 1007596-73-7 ]

Reference： [1]Patent: WO2008/20222,2008,A1

77
[ 13139-12-3 ]
[ 1007596-74-8 ]

Reference： [1]Patent: WO2008/20222,2008,A1

78
[ 13139-12-3 ]
[ 1007596-75-9 ]

Reference： [1]Patent: WO2008/20222,2008,A1

79
[ 13139-12-3 ]
C₂₄H₃₁N₃O₄ [ No CAS ]
C₂₉H₃₉N₃O₆ [ No CAS ]

Reference： [1]Patent: US2018/362550,2018,A1 .Location in patent: Paragraph 0118

80
[ 13139-12-3 ]
vapreotide acetate [ No CAS ]
[ 64-19-7 ]
C₆₂H₇₈N₁₂O₁₁S₂*C₂H₄O₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 2708 - 2719

81
[ 13139-12-3 ]
(-)-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7) disulfide [ No CAS ]
(x)C₂H₄O₂*C₅₄H₇₄N₁₀O₁₂S₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 2708 - 2719

82
[ 13139-12-3 ]
D-Tyr-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr-OH [ No CAS ]
[ 177943-94-1 ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 2708 - 2719

83
[ 13139-12-3 ]
[ 294-90-6 ]
[ 913542-70-8 ]

Reference： [1]Patent: JP2019/43902,2019,A

84
[ 13139-12-3 ]
[ 696-60-6 ]
[ 149505-94-2 ]

Yield	Reaction Conditions	Operation in experiment
97%	In N,N-dimethyl-formamide; at 20℃; for 3h;	To a stirred solution of compound 6 (200 mg, 1.62 mmol) in DMF(4 mL), Boc-OSu (1 eq, 349 mg, 1.62 mmol) was added at room temperature.Upon completion of the reaction after 3 h, the solvent wasremoved under high vacuo and the residue, dissolved in AcOEt, waswashed with brine and H2O. The organic phase was dried with Na2SO4,the solvent was evaporated and the crude product was purified usingcolumn chromatography with AcOEt-petroleum ether (40-60 C) 1:1 aseluent. White solid; yield 350 mg (97%); mp: 83.2-84.8 C (mplit 6987 C); Rf [AcOEt-petroleum ether (40-60 C] 1:1) 0.63; 1H NMR(CDCl3) delta 7.23 (1H, br s, NH), 7.09-7.05 (2H, d, J = 8.0 Hz, Ar-H),6.79-6.75 (2H, d, J = 8,4 Hz, Ar-H), 4.96 (1H, br s, OH), 4.22-4.19(2H, d, J = 5,8 Hz, CH2), 1.46 (9H, s, 3xCH3); 13C NMR (CDCl3) delta156.46, 155.74, 129.79, 128.90, 115.60, 80.07, 44.25, 28.47; MS (ESI)m/z (%) 222.21 [(Mu - H-), 100].

Reference： [1]Bioorganic and medicinal chemistry,2020,vol. 28

85
[ 13139-12-3 ]
methyl 4-((4-(((tert-butoxycarbonyl)amino)methyl)phenoxy)methyl)benzoate [ No CAS ]

Reference： [1]Bioorganic and medicinal chemistry,2020,vol. 28

86
[ 13139-12-3 ]
tert-butyl (4-((4-sulfamoylbenzyl)oxy)benzyl)carbamate [ No CAS ]

Reference： [1]Bioorganic and medicinal chemistry,2020,vol. 28

87
[ 13139-12-3 ]
tert-butyl (4-((4-cyanobenzyl)oxy)benzyl)carbamate [ No CAS ]

Reference： [1]Bioorganic and medicinal chemistry,2020,vol. 28

88
[ 13139-12-3 ]
[ 391668-61-4 ]

Reference： [1]Bioorganic and medicinal chemistry,2020,vol. 28

Same Skeleton Products

Related Products

Historical Records

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 13139-12-3 ] {[proInfo.proName]}

Quality Control of [ 13139-12-3 ]

Related Doc. of [ 13139-12-3 ]

Product Details of [ 13139-12-3 ]

Calculated chemistry of [ 13139-12-3 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 13139-12-3 ]

Application In Synthesis of [ 13139-12-3 ]

[ 13139-12-3 ] Synthesis Path-Upstream 1~3

[ 13139-12-3 ] Synthesis Path-Downstream 1~88

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry